Crinetics Pharmaceuticals, Inc. – NASDAQ:CRNX

Add to watchlist

$30.24

-21.61

-41.68%

Market closed

Open in 3 days

-3.39%

month

-3.39%

quarter

+42.52%

year

Market Cap	4.90B
Enterprise value	N/A

P/E	-5.05
EV/Sales	-6.29
EV/EBITDA	0.18
Price/Sales	0.17
Price/Book	N/A
PEG ratio	0.40
EPS	-3.78

Revenue	N/A
EBITDA	-247.78M
Income	-235.46M
Revenue Q/Q	-76.11%
Revenue Y/Y	-53.93%

Profit margin	-3460.38%
Oper. margin	-3544.06%
Gross margin	0%
EBIT margin	-3544.06%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Profit margin
Jun 2023	988K	-50.97M	-5159.82%
Sep 2023	346K	-57.45M	-16606.36%
Dec 2023	0	-60.09M
Mar 2024	640K	-66.93M	-10457.81%

Crinetics Pharmaceuticals Financials Estimate

Q Y

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Analyst Estimates
Sep 2025	9.36M	-66.47M	-709.57%
Oct 2025	910.6K	-75.75M	-8319.67%
Dec 2025	4.57M	-76.48M	-1672.76%
Mar 2026	5M	-76.62M	-1532.53%

Analysts Price target
Financials & Ratios estimates

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Debt to assets
Jun 2023	293254000	39.13M	13.35%
Sep 2023	641537000	93.78M	14.62%
Dec 2023	635353000	96.24M	15.15%
Mar 2024	978153000	103.22M	10.55%

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Cash Flow
Jun 2023	-45.73M	31.43M	12.65M
Sep 2023	-41.33M	-193.29M	337.87M
Dec 2023	-38.51M	-87.30M	37.92M
Mar 2024	-52.85M	309K	393.57M

Crinetics Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Crinetics Pharmaceuticals
Employees

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Employee count
Aug 2023	210
Sep 2023	210
Oct 2023	210
Nov 2023	210
Dec 2023	210
Jan 2024	210
Feb 2024	210
Mar 2024	290
Apr 2024	290
May 2024	290
Jun 2024	290
Jul 2024	290

Crinetics Pharmaceuticals
Hedge Funds Holdings Q1 2023

29.94% -70.06%

of CRNX is owned by hedge funds

69 -52

hedge funds hold CRNX stock

15.56M -39.32M

shares is hold by hedge funds

CRNX hedge funds holdings changes

Crinetics Pharmaceuticals
Insider Trading

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	30375
Mar 2024	0	119390
Apr 2024	0	55326
May 2024	0	113448
Jun 2024	0	63585
Jul 2024	0	106431
Aug 2024	0	6000
Sep 2024	0	26035
Oct 2024	0	14375
Nov 2024	0	501
Dec 2024	0	10000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	16 Dec 2024	BETZ STEPHEN F. officer: Chief Scientific Officer officer: Chief Scientific Officer	Stock Option (Right to Buy)	2,331	$1.91	$4,452
Option	16 Dec 2024	BETZ STEPHEN F. officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	2,331	$1.91	$4,452
Sale	2 Dec 2024	STRUTHERS RICHARD SCOTT director, officer: President & CEO director, officer: President & ..	Common Stock	10,000	$57.57	$575,700
Sale	22 Nov 2024	KNIGHT JEFF E. officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	501	$56.52	$28,317
Option	3 Oct 2024	PIZZUTI DANA officer: Chief Med and Dev Officer officer: Chief Med and Dev Offi..	Stock option (Right to Buy)	14,375	$16.89	$242,794
Option	3 Oct 2024	PIZZUTI DANA officer: Chief Med and Dev Officer officer: Chief Med and Dev Offi..	Common Stock	14,375	$16.89	$242,794
Sale	3 Oct 2024	PIZZUTI DANA officer: Chief Med and Dev Officer officer: Chief Med and Dev Offi..	Common Stock	14,375	$54.63	$785,306
Option	26 Sep 2024	WILSON MARC officer: CFO	Common Stock	25,000	$15.29	$382,250
Option	26 Sep 2024	WILSON MARC officer: CFO	Common Stock	25,000	$15.29	$382,250
Sale	26 Sep 2024	WILSON MARC officer: CFO	Common Stock	25,000	$51.11	$1,277,750

CRNX insider trading transactions

Crinetics Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS Filling date: 15 Jul 2020 Issue date: 25 Aug 2022	15 Jul 2020	25 Aug 2022
Application	Application CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR Filling date: 16 Feb 2022 Issue date: 18 Aug 2022	16 Feb 2022	18 Aug 2022
Application	Application FORMULATIONS OF A SOMATOSTATIN MODULATOR Filling date: 25 Jan 2022 Issue date: 12 May 2022	25 Jan 2022	12 May 2022
Application	Application NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Filling date: 21 Jan 2022 Issue date: 12 May 2022	21 Jan 2022	12 May 2022
Application	Application FORMULATIONS OF A SOMATOSTATIN MODULATOR Filling date: 7 Sep 2021 Issue date: 10 Mar 2022	7 Sep 2021	10 Mar 2022
Grant	Grant Utility: Formulations of a somatostatin modulator Filling date: 7 Sep 2021 Issue date: 8 Mar 2022	7 Sep 2021	8 Mar 2022
Application	Application SOMATOSTATIN MODULATORS AND USES THEREOF Filling date: 26 Oct 2021 Issue date: 17 Feb 2022	26 Oct 2021	17 Feb 2022
Grant	Grant Utility: Somatostatin modulators and uses thereof Filling date: 19 May 2020 Issue date: 30 Nov 2021	19 May 2020	30 Nov 2021
Application	Application MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Filling date: 8 Feb 2021 Issue date: 5 Aug 2021	8 Feb 2021	5 Aug 2021
Grant	Grant Utility: Somatostatin modulators and uses thereof Filling date: 16 Sep 2019 Issue date: 27 Jul 2021	16 Sep 2019	27 Jul 2021

CRNX patents

Crinetics Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 29 Feb 2024	Q4 2023 Earnings Call Transcript
Q4 2020 30 Mar 2021	Q4 2020 Earnings Call Transcript

CRNX earnings call transcripts

Crinetics Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. R. Scott Struthers (1962) Founder, Pres, Chief Executive Officer & Director	63	$820,330
Dr. Ajay Madan DABT, Ph.D., D.A.B.T. (1968) Chief Devel. Officer	57	$567,530
Mr. Marc J. C. Wilson (1979) Chief Financial Officer & Sec.	46	$527,720

Crinetics Pharmaceuticals
Latest News

Tuesday, 10 December 2024
20:44	Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 9 December 2024
08:00	Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly	globenewswire.com
Thursday, 14 November 2024
16:05	UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting	globenewswire.com
Tuesday, 12 November 2024
23:00	Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript	seekingalpha.com
16:07	Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting	globenewswire.com
16:05	Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Monday, 11 November 2024
16:05	Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 10 October 2024
16:40	Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 8 October 2024
23:55	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock	globenewswire.com
16:01	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock	globenewswire.com
Monday, 7 October 2024
10:23	Did this congressman benefit from a stock buy just before FDA approval?	finbold.com
Thursday, 26 September 2024
16:05	Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly	globenewswire.com
Tuesday, 10 September 2024
16:40	Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 29 August 2024
16:05	Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences	globenewswire.com
Monday, 12 August 2024
16:05	Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 8 August 2024
21:23	Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript	seekingalpha.com
19:01	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates	zacks.com
08:30	Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges	globenewswire.com
Thursday, 1 August 2024
11:06	Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release	zacks.com
Thursday, 18 July 2024
16:05	Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024	globenewswire.com
Wednesday, 10 July 2024
19:29	Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 26 June 2024
14:11	7 Biotech Stocks to Boost Your Portfolio to Peak Health	investorplace.com
Tuesday, 18 June 2024
16:30	EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner	globenewswire.com
Monday, 10 June 2024
18:35	Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 3 June 2024
12:00	Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)	globenewswire.com
12:00	Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly	globenewswire.com
Thursday, 30 May 2024
16:05	Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.	globenewswire.com
Wednesday, 22 May 2024
08:00	Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts	globenewswire.com
Saturday, 11 May 2024
10:09	Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript	Seeking Alpha
Thursday, 9 May 2024
18:36	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 2 Jan 2025

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Seeking Alpha 9 Jul 2024

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Seeking Alpha 23 May 2024

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
Seeking Alpha 28 Nov 2023

Crinetics Pharmaceuticals: Some Caution Warranted
Seeking Alpha 28 Aug 2023

Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly
Seeking Alpha 17 Aug 2023

Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO
Seeking Alpha 25 May 2023

Crinetics Pharmaceuticals And Its Value Proposition In Acromegaly
Seeking Alpha 13 Jun 2022

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Seeking Alpha 24 Apr 2022

Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress

Frequently Asked Questions (FAQ)

What's the price of Crinetics Pharmaceuticals stock today?

One share of Crinetics Pharmaceuticals stock can currently be purchased for approximately $30.24.
When is Crinetics Pharmaceuticals's next earnings date?

Unfortunately, Crinetics Pharmaceuticals's (CRNX) next earnings date is currently unknown.
Does Crinetics Pharmaceuticals pay dividends?

No, Crinetics Pharmaceuticals does not pay dividends.
How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of 4.90B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 15.28% to 4.01M US dollars.
What is Crinetics Pharmaceuticals's stock symbol?

Crinetics Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CRNX".
What is Crinetics Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Crinetics Pharmaceuticals?

Shares of Crinetics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Crinetics Pharmaceuticals's key executives?
Crinetics Pharmaceuticals's management team includes the following people:
- Dr. R. Scott Struthers Founder, Pres, Chief Executive Officer & Director(age: 63, pay: $820,330)
- Dr. Ajay Madan DABT, Ph.D., D.A.B.T. Chief Devel. Officer(age: 57, pay: $567,530)
- Mr. Marc J. C. Wilson Chief Financial Officer & Sec.(age: 46, pay: $527,720)
Is Crinetics Pharmaceuticals founder-led company?

Yes, Crinetics Pharmaceuticals is a company led by its founder Dr. R. Scott Struthers.
How many employees does Crinetics Pharmaceuticals have?

As Jul 2024, Crinetics Pharmaceuticals employs 290 workers.
When Crinetics Pharmaceuticals went public?

Crinetics Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 18 Jul 2018.
What is Crinetics Pharmaceuticals's official website?

The official website for Crinetics Pharmaceuticals is crinetics.com.
Where are Crinetics Pharmaceuticals's headquarters?

Crinetics Pharmaceuticals is headquartered at Building No. 2, San Diego, CA.
How can i contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals's mailing address is Building No. 2, San Diego, CA and company can be reached via phone at 858 450 6464.

Crinetics Pharmaceuticals, Inc.

crinetics.com

Exchange:

NASDAQ

Full time employees:

290

Industry:

Biotechnology

Sector:

Healthcare

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

858 450 6464

Building No. 2
San Diego, CA 92121

CIK: 0001658247
ISIN: US22663K1079
CUSIP: 22663K107